HK Stock Market Move | SINOMAB BIO-B(03681) rose over 5% in the morning and is expected to launch a Phase II clinical trial for SM17 AD as early as the second quarter.

SINOMAB BIO-B (03681) rose by over 5% in the morning, up 4.48% as of press time, at 2.1 Hong Kong dollars, with a turnover of 9.5299 million Hong Kong dollars. On the news front, SINOMAB BIO-B announced that on February 24, 2026, the company's First-in-Class (FIC) treatment product SM17 for inflammatory bowel disease (IBD) patients has received approval for a new drug clinical trial application (IND) from the National Medical Products Administration of China (NMPA). The approval of this IND represents an important milestone for SM17's treatment range to expand from atopic dermatitis (AD) to IBD, covering chronic, debilitating diseases such as Crohn's disease (CD) and ulcerative colitis (UC) with significant unmet medical needs. The company has completed follow-up visits for Phase I bridging studies in healthy volunteers using the subcutaneous injection formulation of SM17. The research data will be used to directly advance the development of Phase II clinical trials for IBD. While advancing the IND, SM17 is currently undergoing bridging studies to transition from intravenous to subcutaneous injection formulation, expected to be completed as early as the first quarter of this year. The company expects to initiate Phase II clinical trials for AD as early as the second quarter of this year. The company believes that expanding the indications of SM17 from AD to IBD presents an important opportunity to address the significant unmet medical needs in this area with significant clinical and commercial value.